7 Hills Pharma’s integrin platform technology enhances immunotherapies, boosting COVID-19 vaccine efficacy and checkpoint inhibitors by improving cell adhesion for stronger immune responses. Learn more from BIO Digital 2020.

7 Hills Pharma launches a COVID-19 vaccine program targeting at-risk elderly, leveraging integrin activator technology to enhance immune responses and improve vaccine effectiveness. Learn more about this breakthrough approach.

Explore how 7HP349, a novel integrin activator, enhances immune responses in cancer therapy and vaccine efficacy. Learn about its role in boosting T cell activation, checkpoint blockade, and pathogen-specific immunity with a strong safety profile.

Discover how the small molecule integrin activator 7HP349 enhances immune checkpoint blockade therapy by promoting T cell infiltration into tumors. Learn about its role in boosting anti-CTLA-4 and anti-PD-L1 efficacy in melanoma and colon cancer models.

Explore the complex relationship between the immune system and cancer, focusing on integrins and cell adhesion molecules in tumor development, immune responses, and cancer immunotherapy strategies.

7 Hills Pharma appoints Dr. Lionel D. Lewis as Chief Medical Officer, bringing extensive immuno-oncology expertise to advance 7HP349 integrin activator for solid tumor treatment. Learn more about this leadership addition.

7 Hills Pharma forms a Scientific Advisory Board with top immuno-oncology experts to advance its integrin activator program, aiming to enhance checkpoint inhibitors and improve cancer immunotherapy effectiveness.

7 Hills Pharma secures a $2M SBIR grant from the NIH, alongside $4M in seed funding, to develop integrin activators that enhance cancer immunotherapy and improve checkpoint inhibitor effectiveness in treating solid tumors.

Discover how cancer vaccines enhance tumor-specific CD8+ T cell trafficking, activation, and infiltration for effective tumor regression. Learn about next-generation immunotherapy strategies to improve cancer vaccine efficacy.

Discover how tumors evade immune responses and limit cancer immunotherapy success. Explore strategies to enhance T-cell and NK-cell infiltration, overcome tumor immune barriers, and improve treatment efficacy.

Discover THI0019, the first small molecule agonist of VLA-4 integrin, designed to enhance progenitor cell adhesion and improve stem cell therapy outcomes. Learn how integrin activation can boost cell retention, migration, and engraftment.

Explore the link between angiogenesis and immunosuppression in cancer. Learn how tumors exploit these processes and discover emerging cancer therapies targeting both vascular growth and immune evasion.

Discover how agonist anti-CD137 monoclonal antibodies enhance T cell recruitment by acting on tumor endothelial cells. Learn about their role in cancer immunotherapy and potential for improving immune infiltration in tumors.

Discover the crucial role of prolonged T cell interactions with antigen-presenting cells (APCs) in immune response regulation. Learn how ICAM-1 and LFA-1 signaling influence T cell activation, memory formation, and immune system efficiency.

Discover how ICAM-1 expression on dendritic cells regulates CD8+ T cell priming, immune memory formation, and cytotoxic T lymphocyte activation. Learn about the role of long-lasting DC-T cell interactions in effective immune responses.

Explore how the Endothelin B receptor (ETBR) inhibits T cell homing, limiting tumor immunotherapy efficacy. Learn about ICAM-1’s role in immune cell infiltration and how ETBR blockade can enhance cancer treatment outcomes.

Explore how tumors evade immune responses by suppressing endothelial adhesion molecules, limiting leukocyte recruitment. Learn about novel strategies to enhance immune cell infiltration and improve cancer immunotherapy outcomes.

Explore how Vascular Adhesion Protein-1 (VAP-1) and ICAM-1 facilitate T cell adhesion to tumor endothelium in hepatocellular carcinoma (HCC). Learn about their role in tumor immune infiltration and potential implications for cancer immunotherapy.

Discover how the cyclic hexapeptide CWLDVC (TBC 772) acts as an alpha4 integrin antagonist, effectively inhibiting human T lymphocyte coactivation and immune cell adhesion. Learn about its potential in targeted immune therapies.

Explore how Alpha 4 Beta 1 (CD49d/CD29) integrin enhances T cell costimulation, driving cytokine induction and transcription factor activation. Learn about its role in immune cell signaling and response modulation.